ARNAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide...

Stats
本日の出来高	0.00
平均出来高	1.47M
時価総額	0.00
EPS	$0 ( 2022-05-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.86
ATR14	$1.142 (1.14%)

Insider Trading

Date	Person	Action	Amount	type
2022-03-11	Nova Tina Susan	Sell	17 776	Common Stock
2022-03-11	Nova Tina Susan	Sell	3 067	Common Stock
2022-03-11	Nova Tina Susan	Sell	4 800	Stock Option (right to buy)
2022-03-11	Nova Tina Susan	Sell	15 000	Stock Option (right to buy)
2022-03-11	Nova Tina Susan	Sell	5 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 416 073 \| Sell: 1 553 839

ボリューム相関

長: 0.35 (neutral)

短: 0.92 (very strong)

Signal:(78.914) Expect same movement, but be aware

Arena Pharmaceuticals Inc 相関

10 最も正の相関
LWAC	0.991
SRAC	0.943
FANH	0.918
MYRG	0.914
TSBK	0.91
TIG	0.908
ALTR	0.904
MNST	0.897
LOPE	0.892
PTMN	0.891

10 最も負の相関
NKTR	-0.97
AGLE	-0.968
INGN	-0.964
CNSP	-0.962
FULC	-0.95
SMSI	-0.947
UPLD	-0.945
ZI	-0.937
CCSI	-0.936
NRBO	-0.933

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Arena Pharmaceuticals Inc 相関 - 通貨/商品

-0.43
( neutral )

0.35
( neutral )

0.51
( weak )

-0.21
( neutral )

0.23
( neutral )

0.37
( neutral )

Arena Pharmaceuticals Inc 財務諸表

Annual	2021
収益:	$54 000.00
総利益:	$0.00 (0.00 %)
EPS:	$-11.26

FY	2021
収益:	$54 000.00
総利益:	$0.00 (0.00 %)
EPS:	$-11.26

FY	2020
収益:	$319 000
総利益:	$319 000 (100.00 %)
EPS:	$-7.39

FY	2019
収益:	$806.43M
総利益:	$0.00 (0.00 %)
EPS:	$7.99

Financial Reports:

No articles found.

Arena Pharmaceuticals Inc

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.